Evaxion Biotech AS (EVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.27M
Last updated: Nov 17, 2026 at 11:01 AM ET
Evaxion Biotech AS (EVAX) Stock Forecast
Analysts expect Evaxion Biotech AS (EVAX) to earn -$0.04 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.02.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.04
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.02
- EPS consensus, revenue $4.67M
- Fiscal year ending Dec 31, 2028
- -$0.03
- EPS consensus, revenue $24.04M
- Next report
- Nov 19, 2026
- Confirmed, before the open
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.04 | -$0.04 to -$0.04 | 2 | N/A | N/A | 4 |
| Dec 31, 2027 | -$0.02 | -$0.03 to $0.00 | 2 | $4.67M | N/A | 4 |
| Dec 31, 2028 | -$0.03 | -$0.24 to $0.18 | 2 | $24.04M | $24.04M to $24.04M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.45 to -$0.36 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.04 | -$0.04 | -$0.04 | -$0.04 | -$0.04 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.04 | N/A |
Frequently Asked Questions About EVAX
What is the EVAX stock forecast?
Consensus analyst estimates put Evaxion Biotech AS's EPS at -$0.04 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.
How do analysts rate EVAX stock?
Of 4 analysts covering Evaxion Biotech AS, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from EVAX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.04, with estimates from -$0.04 to -$0.04 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.02, with estimates from -$0.03 to $0.00 from 2 analysts.
What revenue do analysts expect from Evaxion Biotech AS next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.67M. For the fiscal year ending Dec 31, 2028, the consensus revenue estimate is $24.04M, with estimates from $24.04M to $24.04M.
How many analysts cover EVAX?
4 analysts rate Evaxion Biotech AS stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EVAX pages: Overview, Earnings, Forecast, Valuation, Competitors